PL2968294T3 - 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu - Google Patents

7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu

Info

Publication number: PL2968294T3
Authority: PL; Poland
Prior art keywords: hexahydroimidazo; pyrido; methylbenzyl; pyrimidin; benzyl
Prior art date: 2013-03-13

Application number

PL14775569T

Other languages

English (en)

Inventor

Martin Stogniew

Joshua E Allen

Bhaskara Rao Nallaganchu

Richard S Pottorf

Gary L Olson

Original Assignee

Oncoceutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-13

Filing date

2014-03-13

Publication date

2019-10-31

2014-03-13 Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc

2019-10-31 Publication of PL2968294T3 publication Critical patent/PL2968294T3/pl

Links

206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
RSAQARAFWMUYLL-UHFFFAOYSA-N tic-10 Chemical compound CC1=CC=CC=C1CN1C(CCN(CC=2C=CC=CC=2)C2)=C2C(=O)N2CCN=C21 RSAQARAFWMUYLL-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Endocrinology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL14775569T 2013-03-13 2014-03-13 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu PL2968294T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201361779828P	2013-03-13	2013-03-13
US201361904718P	2013-11-15	2013-11-15
PCT/US2014/025885 WO2014160130A1 (en)	2013-03-13	2014-03-13	Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
EP14775569.8A EP2968294B1 (en)	2013-03-13	2014-03-13	7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer

Publications (1)

Publication Number	Publication Date
PL2968294T3 true PL2968294T3 (pl)	2019-10-31

Family

ID=51527915

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14775569T PL2968294T3 (pl)	2013-03-13	2014-03-13	7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu

Country Status (26)

Country	Link
US (1)	US9265765B2 (pl)
EP (2)	EP2968294B1 (pl)
JP (3)	JP6446025B2 (pl)
KR (2)	KR20220123335A (pl)
CN (2)	CN119954807A (pl)
AU (3)	AU2014244117B2 (pl)
BR (1)	BR112015023256A2 (pl)
CA (2)	CA2905037C (pl)
CY (1)	CY1121735T1 (pl)
DK (1)	DK2968294T3 (pl)
EA (1)	EA037937B1 (pl)
ES (1)	ES2734568T3 (pl)
HR (1)	HRP20191181T1 (pl)
HU (1)	HUE044238T2 (pl)
IL (2)	IL241452B (pl)
LT (1)	LT2968294T (pl)
ME (1)	ME03470B (pl)
MX (2)	MX2015012636A (pl)
NZ (2)	NZ751509A (pl)
PL (1)	PL2968294T3 (pl)
PT (1)	PT2968294T (pl)
RS (1)	RS59013B1 (pl)
SG (2)	SG11201507247WA (pl)
SI (1)	SI2968294T1 (pl)
SM (1)	SMT201900384T1 (pl)
WO (1)	WO2014160130A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS67757B1 (sr)	2011-04-29	2026-03-31	Penn State Res Found	Indukcija malim molekulom trail gena u normalnim i tumorskim ćelijama kao antikancerska terapija
US9376437B2 (en)	2013-03-13	2016-06-28	Oncoceutics, Inc	7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
PL2968294T3 (pl)	2013-03-13	2019-10-31	Oncoceutics Inc	7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
ES2812208T3 (es)	2013-03-14	2021-03-16	Bristol Myers Squibb Co	Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
SMT201900291T1 (it) *	2013-11-15	2019-07-11	Oncoceutics Inc	7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidriomidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, suoi sali e metodi d'uso
KR20200029627A (ko)	2014-03-12	2020-03-18	예다 리서치 앤드 디벨럽먼트 캄파니 리미티드	Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US10519237B2 (en)	2014-03-12	2019-12-31	Yeda Research And Development Co. Ltd	Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en)	2014-03-12	2016-07-19	Yeda Research And Development Co., Ltd	Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en)	2014-03-12	2020-04-14	Yeda Research And Development Co. Ltd	Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
HUE069651T2 (hu) *	2014-03-31	2025-03-28	Scripps Research Inst	Farmakofór TRAIL indukcióra
SMT202500087T1 (it) *	2015-01-30	2025-03-12	Oncoceutics Inc	Derivati di 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, loro sali e loro uso in terapia
CN104860948B (zh)	2015-05-15	2017-09-26	南京盖特医药技术有限公司	咪唑并嘧啶酮类化合物及其制备方法和应用
US10471055B2 (en)	2015-08-17	2019-11-12	Kura Oncology, Inc.	Methods of treating cancer patients with farnesyltransferase inhibitors
KR20170037260A (ko)	2015-09-25	2017-04-04	현대자동차주식회사	차량용 배터리 시스템 및 그 제어 방법
WO2017132661A2 (en)	2016-01-29	2017-08-03	Oncoceutics, Inc.	G protein-coupled receptor (gpcr) modulation by imipridones
MY199595A (en)	2016-03-02	2023-11-08	Eisai R&D Man Co Ltd	Eribulin-based antibody-drug conjugates and methods of use
KR20170110520A (ko) *	2016-03-23	2017-10-11	고려대학교 산학협력단	mTOR 억제제 및 N-아세틸시스테인을 포함하는 간섬유화 억제용 조성물
JP2019513828A (ja)	2016-04-06	2019-05-30	ノクソファームリミティド	改善された薬物動態を有するイソフラボノイド組成物
EP3439642A4 (en) *	2016-04-06	2019-11-13	Noxopharm Limited	IMPROVEMENTS IN RADIOTHERAPY
US11091483B2 (en) *	2016-08-12	2021-08-17	Madera Therapeutics, LLC	Protein kinase regulators
HRP20210544T1 (hr)	2016-11-03	2021-08-20	Kura Oncology, Inc.	Inhibitori farneziltransferaze za uporabu u liječenju raka
EP3565548A4 (en) *	2017-01-04	2020-10-14	The Board of Trustees of the Leland Stanford Junior University	TARGET GENES IN MYC-INDUCED NEOPLASIA
US11040027B2 (en)	2017-01-17	2021-06-22	Heparegenix Gmbh	Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US10172862B2 (en)	2017-01-30	2019-01-08	Oncoceutics, Inc.	Imipridones for gliomas
IT201800004082A1 (it) *	2018-03-29	2019-09-29	Berlin Chemie Ag	Composizioni farmaceutiche antitumorali per terapia combinata
US20200046703A1 (en) *	2018-08-09	2020-02-13	Asymmetric Therapeutics, Llc	Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
JP2022515256A (ja)	2018-12-25	2022-02-17	ソル－ゲルテクノロジーズリミテッド	Ｅｇｆｒ阻害剤を含む組成物による皮膚障害の治療
WO2020147842A1 (zh) *	2019-01-18	2020-07-23	南京明德新药研发有限公司	吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用
EP3725370A1 (en)	2019-04-19	2020-10-21	ImmunoBrain Checkpoint, Inc.	Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
KR20220107229A (ko)	2019-11-28	2022-08-02	인엑스메드 (난징) 컴퍼니 리미티드	암 치료에서 bi853520의 용도
CN115151533B (zh)	2020-01-10	2025-08-08	医疗免疫工程公司	Mek抑制剂及其治疗用途
KR20220137666A (ko) *	2020-02-05	2022-10-12	인엑스메드 (난징) 컴퍼니 리미티드	Bi853520과 화학요법 약물의 병용
WO2021195698A1 (en)	2020-03-30	2021-10-07	Noxopharm Limited	Methods for the treatment of inflammation associated with infection
CN117599041B (zh) *	2024-01-22	2024-05-03	中国人民解放军军事科学院军事医学研究院	去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途
EP4684834A1 (de)	2024-07-26	2026-01-28	BRIU GmbH	Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2150062A1 (de) *	1971-10-07	1973-04-12	Boehringer Sohn Ingelheim	Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4642345A (en)	1980-08-14	1987-02-10	Mead Johnson & Company	6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones
US7635690B2 (en)	1999-01-22	2009-12-22	Emory University	HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
NZ535349A (en)	2002-03-08	2007-01-26	Signal Pharm Inc	JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CN103169729A (zh)	2005-02-18	2013-06-26	阿布拉科斯生物科学有限公司	治疗剂的组合和给予方式以及联合治疗
US20080221135A1 (en)	2005-05-13	2008-09-11	Bristol-Myers Squibb Company	Combination therapy
JP2012502994A (ja)	2008-09-22	2012-02-02	アムジエン・インコーポレーテツド	治療方法
AU2009324464B2 (en)	2008-12-11	2016-05-05	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
US9724337B2 (en)	2009-04-21	2017-08-08	University Of Kentucky Research Foundation	AG-205 for the treatment of breast cancer
DE102010014426A1 (de) *	2010-04-01	2011-10-06	Bayer Schering Pharma Aktiengesellschaft	Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
RS67757B1 (sr) *	2011-04-29	2026-03-31	Penn State Res Found	Indukcija malim molekulom trail gena u normalnim i tumorskim ćelijama kao antikancerska terapija
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
PL2968294T3 (pl)	2013-03-13	2019-10-31	Oncoceutics Inc	7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
HUE069651T2 (hu)	2014-03-31	2025-03-28	Scripps Research Inst	Farmakofór TRAIL indukcióra

2014
- 2014-03-13 PL PL14775569T patent/PL2968294T3/pl unknown
- 2014-03-13 LT LTEP14775569.8T patent/LT2968294T/lt unknown
- 2014-03-13 HR HRP20191181TT patent/HRP20191181T1/hr unknown
- 2014-03-13 NZ NZ751509A patent/NZ751509A/en active IP Right Revival
- 2014-03-13 EA EA201591715A patent/EA037937B1/ru unknown
- 2014-03-13 SI SI201431257T patent/SI2968294T1/sl unknown
- 2014-03-13 WO PCT/US2014/025885 patent/WO2014160130A1/en not_active Ceased
- 2014-03-13 US US14/208,657 patent/US9265765B2/en active Active
- 2014-03-13 DK DK14775569.8T patent/DK2968294T3/da active
- 2014-03-13 CN CN202510107155.3A patent/CN119954807A/zh active Pending
- 2014-03-13 EP EP14775569.8A patent/EP2968294B1/en active Active
- 2014-03-13 BR BR112015023256A patent/BR112015023256A2/pt not_active Application Discontinuation
- 2014-03-13 ES ES14775569T patent/ES2734568T3/es active Active
- 2014-03-13 MX MX2015012636A patent/MX2015012636A/es active IP Right Grant
- 2014-03-13 KR KR1020227029471A patent/KR20220123335A/ko not_active Ceased
- 2014-03-13 CA CA2905037A patent/CA2905037C/en active Active
- 2014-03-13 NZ NZ711948A patent/NZ711948A/en unknown
- 2014-03-13 CN CN201480022856.7A patent/CN105530937A/zh active Pending
- 2014-03-13 KR KR1020157028393A patent/KR102438135B1/ko active Active
- 2014-03-13 SM SM20190384T patent/SMT201900384T1/it unknown
- 2014-03-13 PT PT14775569T patent/PT2968294T/pt unknown
- 2014-03-13 CA CA3204801A patent/CA3204801A1/en active Pending
- 2014-03-13 AU AU2014244117A patent/AU2014244117B2/en not_active Ceased
- 2014-03-13 JP JP2016501988A patent/JP6446025B2/ja active Active
- 2014-03-13 SG SG11201507247WA patent/SG11201507247WA/en unknown
- 2014-03-13 RS RS20190874A patent/RS59013B1/sr unknown
- 2014-03-13 HU HUE14775569 patent/HUE044238T2/hu unknown
- 2014-03-13 SG SG10201808496VA patent/SG10201808496VA/en unknown
- 2014-03-13 ME MEP-2019-197A patent/ME03470B/me unknown
- 2014-03-13 EP EP19171477.3A patent/EP3572083A1/en not_active Withdrawn
2015
- 2015-09-10 IL IL241452A patent/IL241452B/en active IP Right Grant
- 2015-09-11 MX MX2019013643A patent/MX2019013643A/es unknown
2018
- 2018-06-22 JP JP2018119005A patent/JP2018184411A/ja active Pending
2019
- 2019-03-19 AU AU2019201896A patent/AU2019201896A1/en not_active Abandoned
- 2019-07-01 CY CY20191100687T patent/CY1121735T1/el unknown
2020
- 2020-06-23 IL IL275623A patent/IL275623A/en unknown
- 2020-07-01 JP JP2020114024A patent/JP2020172510A/ja active Pending
- 2020-09-14 AU AU2020233606A patent/AU2020233606A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MX2015012636A (es)	2017-02-06
EP2968294B1 (en)	2019-05-01
EA201591715A1 (ru)	2016-07-29
SMT201900384T1 (it)	2019-09-09
SG11201507247WA (en)	2015-10-29
ME03470B (me)	2020-01-20
PT2968294T (pt)	2019-07-19
US20140271540A1 (en)	2014-09-18
BR112015023256A2 (pt)	2017-07-18
CY1121735T1 (el)	2020-07-31
IL241452A0 (en)	2015-11-30
IL275623A (en)	2020-08-31
JP2020172510A (ja)	2020-10-22
AU2019201896A1 (en)	2019-04-11
KR20220123335A (ko)	2022-09-06
CA3204801A1 (en)	2014-10-02
AU2020233606A1 (en)	2020-10-01
HRP20191181T1 (hr)	2019-10-04
AU2014244117A1 (en)	2015-10-08
SI2968294T1 (sl)	2019-08-30
WO2014160130A1 (en)	2014-10-02
NZ711948A (en)	2020-02-28
EP2968294A1 (en)	2016-01-20
CN119954807A (zh)	2025-05-09
JP2018184411A (ja)	2018-11-22
RS59013B1 (sr)	2019-08-30
SG10201808496VA (en)	2018-10-30
IL241452B (en)	2020-07-30
CA2905037C (en)	2023-08-29
EP3572083A1 (en)	2019-11-27
MX2019013643A (es)	2020-02-03
US9265765B2 (en)	2016-02-23
CA2905037A1 (en)	2014-10-02
EA037937B1 (ru)	2021-06-09
NZ751509A (en)	2023-03-31
KR102438135B1 (ko)	2022-08-29
HUE044238T2 (hu)	2019-10-28
AU2014244117B2 (en)	2018-12-20
JP6446025B2 (ja)	2018-12-26
LT2968294T (lt)	2019-07-25
KR20150136602A (ko)	2015-12-07
JP2016512563A (ja)	2016-04-28
DK2968294T3 (da)	2019-07-15
ES2734568T3 (es)	2019-12-10
CN105530937A (zh)	2016-04-27
EP2968294A4 (en)	2016-10-19
HK1217653A1 (en)	2017-01-20
CA2905037E (en)	2014-10-02

Publication	Publication Date	Title
HUE044238T2 (hu)	2019-10-28	7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-hexahidroimidazo[l,2-a]pirido[4,3-d]pirimidin-5(3h)-on rák kezelésénél történõ alkalmazásra
IL288525A (en)	2022-01-01	7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo-[1,2-a] pyrido [3,4-e] pyrimidine-5(1h)-one, analogs and salts thereof, and methods of use for therapy
IL288674A (en)	2022-02-01	7-Benzyl-4-(2-methylbenzyl)-2, 4, 6, 7, 8, 9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidine-5(1h)one, its salts and methods Use
IL246311A0 (en)	2016-08-02	Pyrazolo[5,1-a]pyridine derivatives and methods of using them
ZA201800485B (en)	2020-05-27	Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
GB201516220D0 (en)	2015-10-28	Pyrrolo[2,3-d]pyrimidin-4-amine compounds and their use in treating cancer